Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.
Merck makes waves in Q1 2022 with COVID-19 treatment, cancer portfolio
Breakthrough Therapy Designation, Business, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Earnings per share (EPS), Financials, Forecasts, Keytruda, Market Share, Merck, Pneumococcal Conjugate Vaccines, Pneumococcal Vaccines, Sales, TherapeuticsMerck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.
IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.